Composition
- Active ingredients
- MESORIDAZINE BESYLATE EQ 25MG BASE/ML
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- MESORIDAZINE BESYLATE EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletNDA016774-002 · Discontinued
- MESORIDAZINE BESYLATE EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletNDA016774-003 · Discontinued
- MESORIDAZINE BESYLATE EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletNDA016774-001 · Discontinued
- MESORIDAZINE BESYLATE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletNDA016774-004 · Discontinued
- MESORIDAZINE BESYLATE EQ 25MG BASE/ML · InjectableNDA016775-001 · Discontinued
- MESORIDAZINE BESYLATE EQ 25MG BASE/ML · ConcentrateThis page
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA016997.
At a glance
- Brand name
- Serentil
- Active substance
- mesoridazine besylate
- Route
- Oral
- Dosage form
- Concentrate
- Applicant
- Novartis
- Status
- Discontinued
- FDA approval
- 31 Jan 1972
- Application
- NDA016997-001